Navigation Links
Data from In Vivo Disease Models on Taligen Therapeutics' Pipeline Candidates to be Presented at the XXII International Complement Workshop
Date:9/25/2008

of complement in myocardial ischemia/reperfusion injury and antibody-mediated rejection in a mouse heterotopic heart transplant model

Carl Atkinson*, Yongquan Gong, Yuxiang Huang, Emily Pauling, Martin Goddard, Stephen Tomlinson

Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 196

Oral Presentation:

mAb171

Treatment with a highly inhibitory monoclonal antibody directed to the C3d ligand binding site on human CR2/CD21 suppresses antigen-specific immune responses in vivo

Liudmila Kulik*, Jonathan P. Hannan, Brigitte T. Huber, V. Michael Holers

Oct. 1, 2008, Animal models (Room: Montreal), 9:30 a.m. - 9:45 a.m., Oral 49

About Taligen Therapeutics

Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that are designed to modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. Taligen's headquarters and late-stage research and development operations are located in Cambridge, Mass. The company also maintains a drug discovery operation in Denver under Taligen's chief scientific officer Michael Holers, M.D., which closely collaborates with an international complement biology research community. For more information, visit http://www.taligentherapeutics.com.

This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to development of the Company's product candidates and potential advantages of the Company's technology and product candidates. Actual results could differ materially from those projected and the Compan
'/>"/>

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
2. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
3. Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
4. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
5. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
6. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
7. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
8. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
9. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
10. Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
11. SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 Ellen MacArthur ... kommande tre åren kommer att vara en partner ... cirkulär ekonomi. Efter stiftelsens framgångsrika partnerskap ... Grid, kommer Philips att ansluta sig som partner ... i sin egen verksamhet och stödja stiftelsens arbete ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance ... alarm fatigue. The need to urgently address this ... its Sentinel Event Alert #50 , "Medical device alarm safety ... database, between January 2008 and June 2012, there were 98 ... resulted in death (82%) , 13 resulted in permanent ...
(Date:6/19/2013)... , June 19, 2013   BioCision , ... standardization and handling in many areas of medical ... new patents by the U.S. Patent Office that ... developed to standardize sample handling to ensure the ... in common laboratory procedures. Patent ...
Breaking Medicine Technology:Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 2Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 3Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2
... April 14, 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. ... Company") a leading manufacturer of medical dressings, medical disposables ... in China, today announced that the Company will attend ... Exhibition to be held in the Shenzhen Convention and ...
... Reportlinker.com announces that a new market research ... Endometrial Cancer Therapeutics - Pipeline Assessment and ... http://www.reportlinker.com/p0479825/Endometrial-Cancer-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Endometrial Cancer Therapeutics - ... Summary GlobalData, the ...
Cached Medicine Technology:Winner Medical to Attend 65th CMEF Spring11 Exhibition in Shenzhen 2Winner Medical to Attend 65th CMEF Spring11 Exhibition in Shenzhen 3Winner Medical to Attend 65th CMEF Spring11 Exhibition in Shenzhen 4Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10
(Date:6/19/2013)... TX (PRWEB) June 19, 2013 Chrysler made ... concerning a recall of 2.7 million Jeeps. The Jeep models ... 2002-2007 Jeep Liberty, which according to the NHTSA are vulnerable ... gas tanks in these models are rear-mounted and have been ... agency findings show the Grand Cherokee with 32 rear-end crashes, ...
(Date:6/19/2013)... June 19, 2013 Amber Roberson ... RWI Benefits, LLC, Native Care Health, LLC and ... of Health Underwriters’ (NAHU) new professional development course ... (PPACA). This continuing education course for agents has ... will receive eleven education credits from the Missouri ...
(Date:6/19/2013)... New York, New York (PRWEB) June 19, 2013 ... involving pancreatitis and pancreatic cancer continue to mount in ... the U.S. Food & Drug Administration (FDA) recently held ... other diabetes drugs known as incretin mimetics. According ... may seek additional data from the makers of Januvia ...
(Date:6/19/2013)... 2013 The Journal of Parasitology – ... computer software, it creates questions of ethics. For scientific ... an already published case shows, scientific publications need clear ... The Journal of Parasitology features a commentary ... 2004 article published in the Journal of the New ...
(Date:6/19/2013)... led by researchers at The University of Texas MD ... show remarkable promise for the treatment of relapsed or ... interim findings of the 18-center Phase 2 study were ... Medicine . Previous interim findings were presented in December ... Meeting and Exposition. , Unprecedented results, fewer ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... it has been found that students who are well fed ... ,The study was done at Cornell's Early Childhood Centre. ... development especially in reading. ,This phenomenon is ... do not have enough to eat due to poverty in ...
... treatment medicine acclaimed the world over Tamiflu now will be ... firm Roche to make a generic version of its anti-flu ... The company is Hetero Drugs. ,The drug is ... future pandemic of bird flu in humans. ,The Swiss drugs ...
... Indian American Scientist Dr. Henry Daniell has produced a ... plant. The new gene transfer technique to tobacco plants ... symptoms and rashes involved in conventional anthrax vaccine fermentation ... of 360 million doses in one acre of tobacco ...
... company that extracts chemicals from plants, plans to use used ... drug that treat bird flu.// ,The trees contain ... Biolyse said today in a statement. The acid is used ... star anise trees in China, Biolyse said. ,Tamiflu ...
... larger brains have better intellect, according to McMaster University’s ... said that there were differences between women and men. ... Brain also said, said that in women, verbal intelligence ... of the verbal IQ score. ,However, ...
... of the rising rates of infection with C.difficile among ... mutation of the microorganism into a more virulent form.// ... manifest in individuals with resistance to antibiotics. ... non-hospitalized patients has created much panic among the scientific ...
Cached Medicine News:Health News:Christmas trees to yield key Tamiflu ingredient 2Health News:Rising Rates Of C.Difficile Infection Among Non-Hospitalized Patients 2
The Advia 60 is designed to deliver powerful performance in a small package....
AcT 5diff OV enables low-volume labs to advance to 5-part differential analysis at an affordable price. This analyzer delivers accurate test results and a user-friendly software interface in a compac...
... three-dimensional VCS technology, providing ... efficiency in white cell ... With its reputation for ... is an affordable solution ...
... 750 analyzer is equipped with ... random access capabilities. These advancements ... pre-sorting of samples and speed ... system, you can improve overall ...
Medicine Products: